Literature DB >> 26754675

Prognostic significance of tumor regression in lymph nodes after neoadjuvant therapy for rectal carcinoma.

M J Fernández-Aceñero1, M Granja2, J Sastre2, B García-Paredes2, L Estrada3.   

Abstract

Neoadjuvant therapy (NAT) is mainly indicated for locally advanced rectal carcinoma. Many reports have shown that regression of the primary tumor is a prognostic factor. However, few reports to date have analyzed the potential prognostic significance of lymph node regression in rectal carcinoma. The aim of the present study is to describe the pattern of tumor regression in lymph nodes after NAT for rectal carcinoma and its potential prognostic significance. We have retrospectively reviewed 106 cases of rectal carcinoma treated at a single institution. We have retrieved data from the patients and reviewed the histopathological slides to evaluate tumor regression both of the primary tumor and of LN metastases. Prognosis has been defined both in terms of disease-free survival (DFS) and disease-specific survival (DSS). Of the patients, 16% showed complete response of the primary tumor, while 24% showed poor response, according to the CAP regression grading system. Absence of lymph node involvement after therapy was found in 80% of the patients (ypN0 cases), while 20% were ypN+. We reviewed 639 LN; 85 were involved by tumor, and 170 showed histological signs of tumor regression. The main pattern of tumor regression in lymph nodes was fibrosis (66.3%), followed by hystiocytosis (29.1%) and mucin pools (4.6%). We found histological signs of regression in 57% of ypN0 cases and 76% of ypN+ cases. We found a significant association between regression grade of the primary tumor and of lymph node metastases. For ypN0 patients with persistence of the primary tumor after NAT, the median DFS was significantly shorter in patients showing tumor regression in the LN. In a Cox multivariate survival model for DFS, this prognostic influence was independent of the regression grade of the primary tumor and also of the ypTNM stage. We found no significant association between any factor and DSS. The pattern of tumor regression in lymph nodes was not significantly associated with prognosis. Tumor regression in lymph nodes is an important prognostic factor in rectal carcinoma after NAT and should be specifically looked for and included in pathology reports.

Entities:  

Keywords:  Lymph nodes; Neoadjuvant therapy; Prognosis; Rectal tumor; Regression

Mesh:

Year:  2016        PMID: 26754675     DOI: 10.1007/s00428-015-1901-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  20 in total

1.  Number of lymph nodes after neoadjuvant therapy for rectal cancer: How many are needed?

Authors:  Stefano Scabini; Valter Ferrando
Journal:  World J Gastrointest Surg       Date:  2012-02-27

2.  Tumour regression and mesorectal lymph node changes after intensified neoadjuvant chemoradiation for carcinoma of the rectum.

Authors:  Friedrich Prall; Michael Wöhlke; Gunther Klautke; Leif Schiffmann; Rainer Fietkau; Malte Barten
Journal:  APMIS       Date:  2006-03       Impact factor: 3.205

3.  Lymph node retrieval after preoperative chemoradiotherapy for rectal cancer.

Authors:  Daniel C Damin; Mário A Rosito; Paulo C Contu; Cláudio Tarta; Paulo R Ferreira; Lucia M Kliemann; Gilberto Schwartsmann
Journal:  J Gastrointest Surg       Date:  2012-05-23       Impact factor: 3.452

4.  Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision?

Authors:  R Hughes; R Glynne-Jones; J Grainger; P Richman; A Makris; M Harrison; R Ashford; R A Harrison; J I Livingstone; P J McDonald; J Meyrick Thomas; I C Mitchell; J M A Northover; R Phillips; M Wallace; A Windsor; J R Novell
Journal:  Int J Colorectal Dis       Date:  2005-04-30       Impact factor: 2.571

5.  Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy.

Authors:  Lorena Losi; Gabriele Luppi; Margherita Gavioli; Francesco Iachetta; Federica Bertolini; Roberto D'Amico; Gordana Jovic; Filippo Bertoni; Anna Maria Falchi; Pier Franco Conte
Journal:  Int J Colorectal Dis       Date:  2005-11-30       Impact factor: 2.571

6.  Rectal cancer.

Authors:  Al B Benson; Tanios Bekaii-Saab; Emily Chan; Yi-Jen Chen; Michael A Choti; Harry S Cooper; Paul F Engstrom; Peter C Enzinger; Marwan G Fakih; Charles S Fuchs; Jean L Grem; Steven Hunt; Lucille A Leong; Edward Lin; Michael G Martin; Kilian Salerno May; Mary F Mulcahy; Kate Murphy; Eric Rohren; David P Ryan; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; William Small; Constantinos T Sofocleous; Alan P Venook; Christopher G Willett; Deborah A Freedman-Cass; Kristina M Gregory
Journal:  J Natl Compr Canc Netw       Date:  2012-12-01       Impact factor: 11.908

7.  A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.

Authors:  Keith N Ogston; Iain D Miller; Simon Payne; Andrew W Hutcheon; Tarun K Sarkar; Ian Smith; A Schofield; Steven D Heys
Journal:  Breast       Date:  2003-10       Impact factor: 4.380

8.  Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy.

Authors:  Taeryool Koo; Changhoon Song; Jae-Sung Kim; Kyubo Kim; Eui Kyu Chie; Sung-Bum Kang; Keun-Wook Lee; Jee Hyun Kim; Seung-Yong Jeong; Tae-You Kim
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

9.  The effect of preoperative chemoradiotherapy on lymph nodes harvested in TME for rectal cancer.

Authors:  Stefano Scabini; Fabrizio Montecucco; Alessio Nencioni; Gabriele Zoppoli; Marina Sartini; Edoardo Rimini; Andrea Massobrio; Luisito De Marini; Alessandro Poggi; Roberto Boaretto; Emanuele Romairone; Alberto Ballestrero; Valter Ferrando
Journal:  World J Surg Oncol       Date:  2013-11-18       Impact factor: 2.754

10.  New tumor regression grade for rectal cancer after neoadjuvant therapy and radical surgery.

Authors:  Jun Li; Hao Liu; Junjie Hu; Sai Liu; Jie Yin; Feng Du; Jiatian Yuan; Bo Lv
Journal:  Oncotarget       Date:  2015-12-08
View more
  3 in total

Review 1.  Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy.

Authors:  Rupert Langer; Karen Becker
Journal:  Virchows Arch       Date:  2017-09-16       Impact factor: 4.064

2.  Significance of tumour regression in lymph node metastases of gastric and gastro-oesophageal junction adenocarcinomas.

Authors:  Daniel Reim; Alexander Novotny; Helmut Friess; Julia Slotta-Huspenina; Wilko Weichert; Katja Ott; Bastian Dislich; Sylvie Lorenzen; Karen Becker; Rupert Langer
Journal:  J Pathol Clin Res       Date:  2020-05-13

Review 3.  Lymph node regression grading of locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.

Authors:  Lei He; Juan Xiao; Ping Zheng; Lei Zhong; Qian Peng
Journal:  World J Gastrointest Oncol       Date:  2022-08-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.